Eli Lilly and Co., partners with Boston biotech company to develop cancer treatment

Binghui Huang, Indianapolis Star
·1 min read

Eli Lilly and Co., is working with Boston-based biotechnology company, Aktis Oncology, to develop cancer treatment, Aktis announced Tuesday.

As a part of the deal between the two companies, Aktis will receive $60 million and another $1.1 billion in royalties for reaching certain milestones in development of new drugs. Lilly will get the rights to develop treatments discovered by Aktis.

“We are pleased to partner with Lilly in efforts to increase the number of patients that can derive meaningful clinical benefit from targeted radiopharmaceuticals,” Matthew Roden, President and Chief Executive Officer of Aktis Oncology, said in a statement.

Binghui Huang can be reached at 317-385-1595 and Bhuang@gannett.com

This article originally appeared on Indianapolis Star: Eli Lilly and Co., partners with Boston biotech company on cancer drugs